Figure 3
From: TCR γ4δ1-Engineered αβT Cells Exhibit Effective Antitumor Activity
Cytokine production and proliferative capacity of TCRγ4δ1-engineered αβT cells. (A) Expression of IL-2 and IFN-γ in resting TCRγ4δ1-engineered αβT cells. Resting mock- and TCRγ4δ1-engineered αβT cells were incubated with HepG2 at an effector-to-target ratio of 3:1 for 6 h with BFA, and the expression of intracellular IL-2 and IFN-γ was determined by flow cytometry. (B) Expression of IL-2 and IFN-γ in the nonresting TCRγ4δ1-engineered αβT cells. The nonresting mock- and TCRγ4δ1-engineered αβT cells were incubated with HepG2 at an effector-to-target ratio of 3:1 for 6 h with BFA, and expression of intracellular IL-2 and IFN-γ was determined by flow cytometry. (C) Expression of intracellular Ki67 in TCRγ4δ1-engineered αβT cells. Mock- and TCRγ4δ1-engineered αβT cells were stimulated with plate-bound anti-TCRγδ for 6 h, and the expression of Ki67 was examined by flow cytometry. Shown is a representative FCM analysis of cytokines and Ki67. (IL, interleukin; IFN, interferon; BFA, brefeldin A.)